Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 ^T315I -compound mutations.

Autor: Gleixner KV; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Filik Y; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Berger D; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Schewzik C; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Stefanzl G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Sadovnik I; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Degenfeld-Schonburg L; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Eisenwort G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Schneeweiss-Gleixner M; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.; Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna Austria., Byrgazov K; Children's Cancer Research Institute (CCRI) Vienna, Austria., Sperr WR; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Mayer J; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno Czech Republic., Lion T; Children's Cancer Research Institute (CCRI) Vienna, Austria., Valent P; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.

Publikováno v: American journal of cancer research [Am J Cancer Res] 2021 Sep 15; Vol. 11 (9), pp. 4470-4484. Date of Electronic Publication: 2021 Sep 15 (Print Publication: 2021).

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Autor: Pérez-Lamas, Lucía¹ (AUTHOR), Luna, Alejandro¹ (AUTHOR), Boque, Concepción² (AUTHOR), Xicoy, Blanca³ (AUTHOR), Giraldo, Pilar⁴ (AUTHOR), Pérez López, Raúl⁵ (AUTHOR), Ruiz Nuño, Concepción⁶ (AUTHOR), De las Heras, Natalia⁷ (AUTHOR), Mora Casterá, Elvira⁸ (AUTHOR), López Marín, Javier⁹ (AUTHOR), Segura Díaz, Adrián¹⁰ (AUTHOR), Gómez, Valle¹¹ (AUTHOR), Vélez Tenza, Patricia¹² (AUTHOR), Sierra Pacho, Magdalena¹³ (AUTHOR), Vera Goñi, Juan Antonio¹⁴ (AUTHOR), Moreno Vega, Melania¹⁵ (AUTHOR), Alvarez-Larrán, Alberto¹⁶ (AUTHOR), Cortés, Montse¹⁷ (AUTHOR), Pérez Encinas, Manuel¹⁸ (AUTHOR), Carrascosa Mastell, Patricia¹⁹ (AUTHOR)

Publikováno v: Cancers. Feb2023, Vol. 15 Issue 4, p1045. 13p.

The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants.

Autor: Wu Ye, Xia Wu, Xiaojia Wang, Xiaoyu Wei, Yuqian Tang, Xianfeng Ouyang, Yuping Gong

Publikováno v: Frontiers in Pharmacology; 10/3/2022, Vol. 13, p1-17, 17p